[article] 
inJournal of Autism and Developmental Disorders > 48-9 (September 2018) . - p.3051-3060

Titre :	A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder
Type de document :	Texte imprimé et/ou numérique
Auteurs :	L. K. WINK, Auteur ; R. ADAMS, Auteur ; P. S. HORN, Auteur ; C. R. TESSIER, Auteur ; A. P. BANTEL, Auteur ; M. HONG, Auteur ; R. C. SHAFFER, Auteur ; Ernest V. PEDAPATI, Auteur ; C. A. ERICKSON, Auteur
Article en page(s) :	p.3051-3060
Langues :	Anglais (eng)
Mots-clés :	Autism  Autism spectrum disorder  Erk  Extracellular signal related kinase  Irritability  Riluzole
Index. décimale :	PER Périodiques
Résumé :	Riluzole is a glutamatergic modulator of particular interest in autism spectrum disorder (ASD). In this 12-week randomized, double-blind, placebo-controlled, crossover pilot study we evaluated the safety and tolerability of 5-week of adjunctive riluzole treatment (vs. 5-week of placebo, with 2-week washout period) targeting ASD-associated drug-refractory irritability in eight individuals age 12-25 years. All participants tolerated riluzole 200 mg per day, however there were no statistically significant findings for the overall treatment effect, the treatment effect by week within period of the study, or a cross-over effect across the periods of the study on the Clinical Global Impression Improvement Scale or the Aberrant Behavior Checklist Irritability subscale. The results of this trial indicate that 5-week of riluzole treatment was well tolerated, but had no significant effect on the target symptoms. Trial Registration ClinicalTrials.gov Identifier NCT02081027, Registered 5 August 2013, First participant enrolled 19 September 2013.
En ligne :	http://dx.doi.org/10.1007/s10803-018-3562-5
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=367

[article] A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / L. K. WINK, Auteur ; R. ADAMS, Auteur ; P. S. HORN, Auteur ; C. R. TESSIER, Auteur ; A. P. BANTEL, Auteur ; M. HONG, Auteur ; R. C. SHAFFER, Auteur ; Ernest V. PEDAPATI, Auteur ; C. A. ERICKSON, Auteur . - p.3051-3060.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 48-9 (September 2018) . - p.3051-3060

Mots-clés :	Autism  Autism spectrum disorder  Erk  Extracellular signal related kinase  Irritability  Riluzole
Index. décimale :	PER Périodiques
Résumé :	Riluzole is a glutamatergic modulator of particular interest in autism spectrum disorder (ASD). In this 12-week randomized, double-blind, placebo-controlled, crossover pilot study we evaluated the safety and tolerability of 5-week of adjunctive riluzole treatment (vs. 5-week of placebo, with 2-week washout period) targeting ASD-associated drug-refractory irritability in eight individuals age 12-25 years. All participants tolerated riluzole 200 mg per day, however there were no statistically significant findings for the overall treatment effect, the treatment effect by week within period of the study, or a cross-over effect across the periods of the study on the Clinical Global Impression Improvement Scale or the Aberrant Behavior Checklist Irritability subscale. The results of this trial indicate that 5-week of riluzole treatment was well tolerated, but had no significant effect on the target symptoms. Trial Registration ClinicalTrials.gov Identifier NCT02081027, Registered 5 August 2013, First participant enrolled 19 September 2013.
En ligne :	http://dx.doi.org/10.1007/s10803-018-3562-5
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=367